Experience with the long-term use of desmopressin for nocturnal enuresis in children and adolescents

BJU International

Volumn 89, Issue 4, 2002, Pages 420-425

  Van Kerrebroeck, P E V ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN; VASOPRESSIN;

BIOCHEMISTRY; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; HEMATOLOGY; HUMAN; LONG TERM CARE; NOCTURNAL ENURESIS; ONSET AGE; PRIORITY JOURNAL; RECURRENT DISEASE; RESPONSE TIME; REVIEW;

ADOLESCENT; CHILD; CLINICAL TRIALS; DEAMINO ARGININE VASOPRESSIN; ENURESIS; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; RENAL AGENTS; TREATMENT OUTCOME; VASOPRESSINS;

EID: 0036223302     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-4096.2001.01546.x     Document Type: Review

References (36)

1. The burden of nocturnal enuresis
2. Enuresis nocturna in adults
3. Self-esteem before and after treatment in children with nocturnal enuresis and urinary incontinence
4. Nocturnal enuresis. Economic impacts and self-esteem preliminary research results
5. Pathophysiology and impact of nocturnal enuresis
6. Efficacy, safety, and dosing of desmopressin for nocturnal enuresis in Europe
7. Nocturnal enuresis. Experience with long-term use of intranasally administered desmopressin
8. Prevalence and risk factors for childhood nocturnal enuresis
9. Behandeling van enuresis nocturna bij volwassenen
10. Are repeated desmopressin treatment attempts successful?
11. Nocturnal enuresis: A suggestion for a European treatment strategy
12. Desmopressin for nocturnal enuresis in children
13. Desmopressin acetate and nocturnal enuresis: How much do we know?
14. Clinical perspectives in primary nocturnal enuresis
15. Long-term double-blind cross-over study of desmopressin intranasal spray in the management of nocturnal enuresis
16. Long-term use and tapered dose reduction of intranasal desmopressin in the treatment of enuretic children
17. Long-term treatment with desmopressin in children with primary monosymptomatic nocturnal enuresis: An open multicentre study
18. Long-term use of desmopressin tablets in adolescents and adults with primary nocturnal enuresis (PNE)
19. Desmopressin tablets in the treatment of severe nocturnal enuresis in adolescents
20. Long-term treatment of nocturnal enuresis with desmopressin intranasal spray
21. Efficacy and safety during long-term treatment of primary monosymptomatic nocturnal enuresis with desmopressin
22. Treatment of primary nocturnal enuresis persisting into adulthood
23. The Swedish Enuresis Trial (SWEET): Longterm use of desmopressin in primary monosymptomatic nocturnal enuresis. Preliminary results
24. Enuresis and spontaneous cure rate. Study of 1129 enuretics
25. Desmopressin in the treatment of severe nocturnal enuresis in adolescents - A 7-year follow-up study
26. Long-term treatment with desmopressin in children with primary nocturnal enuresis. An international multicenter study
27. Development of fat tissue and body mass index from infancy to adulthood
28. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood
29. Swedish population reference standards for height, weight and body mass index attained at 6-16 years (girls) or 19 years (boys)
30. Body mass index centile charts to assess fatness of British children
31. Intranasal desmopressinassociated hyponatremia, a case report and literature review
32. Hyponatremia in patients with nocturnal enuresis treated with DDAVP
33. Impermeability of the blood-cerebrospinal fluid barrier to 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus
34. Assessment of the safety of regular DDAVP therapy in primary nocturnal enuresis
35. Long-term treatment of nocturnal enuresis with desmopressin. A follow-up study